Journal article 205 views 48 downloads
Perspective on Schistosomiasis Drug Discovery: Highlights from a Schistosomiasis Drug Discovery Workshop at Wellcome Collection, London, September 2022
,
Rana Afshar,
Beatriz Baragaña ,
Amaya L. Bustinduy,
Conor R. Caffrey ,
James J. Collins,
Daniela Fusco,
Amadou Garba,
Mark Gardner,
Mireille Gomes,
Karl F. Hoffmann ,
Michael Hsieh,
Nathan C. Lo,
Case W. McNamara ,
Justin Komguep Nono,
Gilda Padalino ,
Kevin D. Read ,
Meta Roestenberg,
Thomas Spangenberg ,
Sabine Specht,
Ian H. Gilbert
ACS Infectious Diseases, Volume: 9, Issue: 5, Pages: 1046 - 1055
Swansea University Author:
Gilda Padalino
-
PDF | Version of Record
Copyright © 2022 The Authors. Published by American Chemical Society. Distributed under the terms of a Creative Commons Attribution 4.0 License (CC BY 4.0).
Download (4.68MB)
DOI (Published version): 10.1021/acsinfecdis.3c00081
Abstract
In September 2022, the Drug Discovery Unit at the University of Dundee, UK, organised an international meeting at the Wellcome Collection in London to explore the current clinical situation and challenges associated with treating schistosomiasis. The aim of this meeting was to discuss the need for n...
| Published in: | ACS Infectious Diseases |
|---|---|
| ISSN: | 2373-8227 2373-8227 |
| Published: |
American Chemical Society (ACS)
2023
|
| Online Access: |
Check full text
|
| URI: | https://cronfa.swan.ac.uk/Record/cronfa64494 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract: |
In September 2022, the Drug Discovery Unit at the University of Dundee, UK, organised an international meeting at the Wellcome Collection in London to explore the current clinical situation and challenges associated with treating schistosomiasis. The aim of this meeting was to discuss the need for new treatments in view of the clinical situation and to ascertain what the key requirements would be for any potential new anti-schistosomals. This information will be essential to inform ongoing drug discovery efforts for schistosomiasis. We also discussed the potential drug discovery pathway and associated criteria for progressing compounds to the clinic. To date, praziquantel (PZQ) is the only drug available to treat all species causing schistosomiasis, but it is often unable to completely clear parasites from an infected patient, partially due to its inactivity against juvenile worms. PZQ-mediated mass drug administration campaigns conducted in endemic areas (e.g., sub-Saharan Africa, where schistosomiasis is primarily prevalent) have contributed to reducing the burden of disease but will not eliminate the disease as a public health problem. The potential for Schistosoma to develop resistance towards PZQ, as the sole treatment available, could become a concern. Consequently, new anthelmintic medications are urgently needed, and this Perspective aims to capture some of the learnings from our discussions on the key criteria for new treatments. |
|---|---|
| Keywords: |
Schistosomiasis, Schistosoma, neglected tropical disease, infectious disease, drug discovery, therapeutics, anthelmintics, target product profile |
| College: |
Faculty of Medicine, Health and Life Sciences |
| Funders: |
This meeting was funded by a Wellcome Trust award (222153/Z/20/Z) which also helped cover travel expenses for attendees from Low and Middle Income Countries. |
| Issue: |
5 |
| Start Page: |
1046 |
| End Page: |
1055 |